Amides of acetic and propionic acids

1. A compound represented by formula (I)

wherein:

R 1 represents a 1-azabicyclo[m.n.p]alkyl radical having 7 to 11 ring atoms, wherein the bicycloalkyl radical is optionally substituted by (C 1 -C 6 )-alkyl;

m represents a value of 2 or 3;

n represents a value of 2 or 3;

p represents a value of 1, 2, or 3;

A represents a methylene or an ethylene;

R 2 represents a 8- to 10-membered ring comprising heteroaryl, naphthyl, or azulenyl, wherein the ring is optionally substituted by a radical selected from the group of halogen, formyl, —CO—NR 4 R 5 , —CO—OR 6 , —NR 7 R 8 , —NR 9 —CO—R 10 , cyano, trifluoromethyl, trifluoromethoxy, nitro, optionally hydroxyl, amino, —NH—CO—R 11 , or cyano-substituted (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy, (C 1 -C 6 )-alkylthio, wherein the R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 independently represent hydrogen, (C 1 -C 6 )-alkyl, phenyl, or benzyl; and

R 3 represents a hydrogen or (C 1 -C 6 )-alkyl; or

a physiological acceptable salt, enantiomer, or diasteromer thereof.

2. The compound of claim 1 , wherein R 1 represents 1-azabicyclo[2.2.2]oct-3-yl.

3. The compound of claim 2 , wherein:

A represents a methylene;

R 2 represents benzotriazolyl, benzothiophenyl, quinolinyl, benzopyrazinyl, or naphthyl, wherein the ring is optionally substituted by 1 to 3 radicals selected from the group of hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio; and

R 3 is hydrogen.

4. The compound of claim 2 , wherein:

A represents a methylene,

R 2 represents benzothiophenyl, quinolinyl, or naphthyl, wherein the ring is optionally substituted by 1 to 2 radicals selected from the group of hydrogen, fluorine, chlorine, bromine, nitro; and

R 3 is hydrogen.

5. A process of preparing the compound of formula (I) of claim 1 , comprising:

i) reacting a compound of formula (II) with a compound of formula (III) to form the compound of formula (I); and

ii) optionally converting the formed compound of formula (I) with an appropriate (i) solvent, and/or (ii) base or acid, into the physiological acceptable salt, enantiomer, or diasteromer of said formed compound of formula (I);

wherein:

a) the compound of formula (II) is represented by:

wherein R 1 and A independently represent the meaning indicated in claim 1 , and X represents a hydroxy or a suitable leaving group;

b) the compound of formula (III) is represented by:

R 2 R 3 NH  (III),

wherein R 2 and R 3 independently represent the meaning indicated in claim 1 .

6. A pharmaceutical composition, comprising:

i) a compound represented by formula (I)

wherein:

R 1 represents a 1-azabicyclo[m.n.p] alkyl radical having 7 to 11 ring atoms, wherein the bicycloalkyl radical is optionally substituted by (C 1 -C 6 )-alkyl;

m represents a value of 2 or 3;

n represents a value of 2 or 3;

p represents a value of 1, 2, or 3;

A represents a methylene or an ethylene;

R 2 represents a 8- to 10-membered ring comprising heteroaryl, naphthyl, or azulenyl, wherein the ring is optionally substituted by a radical selected from the group of halogen, formyl, —CO—NR 4 R 5 , —CO—OR 6 , —NR 7 R 8 , —NR 9 —CO—R 10 , cyano, trifluoromethyl, trifluoromethoxy, nitro, optionally hydroxyl, amino, —NH—CO—R 11 , or cyano-substituted (C 1 -C 6 )-alkyl, (C 1 -C 6 )- alkoxy, (C 1 -C 6 )-alkylthio, wherein the R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 independently represent hydrogen, (C 1 -C 6 ) -alkyl, phenyl, or benzyl; and

R 3 represents a hydrogen or (C 1 -C 6 )-alkyl; or

a physiological acceptable salt, enantiomer, or diasteromer thereof; and

ii) one or more pharmaceutically acceptable carriers or excipients.

7. The pharmaceutical composition of claim 6 , wherein R 1 represents 1-azabicyclo[2.2.2]oct-3-yl.

8. The pharmaceutical composition of claim 7 , wherein:

A represents a methylene;

R 2 represents benzotriazolyl, benzothiophenyl, quinolinyl, benzopyrazinyl, or naphthyl, wherein the ring is optionally substituted by 1 to 3 radicals selected from the group of hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio; and

R 3 is hydrogen.

9. The pharmaceutical composition of claim 7 , wherein:

A represents a methylene,

R 2 represents benzothiophenyl, quinolinyl, or naphthyl, wherein the ring is optionally substituted by 1 to 2 radicals selected from the group of hydrogen, fluorine, chlorine, bromine, nitro; and

R 3 is hydrogen.

10. A method of producing a medicament for improving perception, concentration, learning and/or memory, comprising: mixing the compound of claim 1 with one or more pharmaceutically acceptable carriers or excipients.

11. A method of producing a medicament for treating and/or prophylaxis of an impairment of perception, concentration, learning and/or memory, comprising:

mixing the compound of claim 1 with one or more pharmaceutically acceptable carriers or excipients.